JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
Allist Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
University of Washington
RenJi Hospital
University of Kentucky